Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-03-10

Clinical Trial Update: A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms [Phase 2]

View source ↗

Summary

Phase 2 trial of BAY3427080 (NT-814) in moderate to severe post-menopausal vasomotor symptoms completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BAY3427080 (NT-814) (NT-814)

Snippet

Sponsor: Bayer | Conditions: Menopause, Hot Flashes | Phase 2 | Status: COMPLETED | Results posted: 2023-03-10